Skip to search formSkip to main contentSkip to account menu

belatacept

Known as: CD152 antigen, CTLA4-Ig 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background Several studies in solid organ transplantation have shown a correlation between gender-match and risk of graft loss… 
2018
2018
Introduction Kidney graft loss in simultaneous pancreas and kidney (SPK) recipients can be associated with worsened pancreas… 
2018
2018
Introduction Although they represent a rapidly growing population, elderly organ transplant recipients are underrepresented in… 
2016
2016
Abstract : The point of our study is to analyze the immune mechanisms contributing to rejection of vascularized composite… 
2016
2016
Post-transplant diabetes mellitus is a major complication after transplantation and is associated with reduced allograft and… 
Review
2016
Review
2016
Objective: The objective of this selective EBM review is to determine whether or not belatacept improves patient/graft survival… 
2012
2012
  • 2012
  • Corpus ID: 261103611
Immunosuppressive therapy designed to prevent kidney graft rejection usually consists of a triple-drug combination including a… 
2011
2011
Patients treated with belatacept (Nulojix) are at an increased risk for developing 2 potentially fatal complications: post… 
Review
2007
Review
2007
When using immunosuppressant agents in renal transplantation, achieving low rejection rates while minimizing long-term toxicities… 
2005
2005
Objective To investigate the feasibility of prolonged cardiac allograft survival by means of intracornary infusion with CTLA4-Ig…